

CORRECTION

In the article “Impact of the New ACC/AHA Guidelines on the Treatment of High Blood Cholesterol in a Managed Care Setting” published in November 2014 (Vol 7, No 8, pages 430-443), the study period was January 1, 2013, to December 31, 2013, rather than November 1, 2012, to October 31, 2013. In addition, the total study population was 14,114,500, rather than 25,705,722; the commercial population was 4,402,866, rather than

14,661,302; the Medicaid population was 2,173,914, rather than 3,313,910; and the Medicare population was 7,537,720, rather than 7,730,510. These population data affect the percentages cited in the body of the article and are also appearing in Table 3, Table 4, and Figure 2, which are corrected below. The overall results and conclusion of the study have not been affected. The article is corrected at www.AHDBonline.com. ■

Figure 2 Projected Percentage of the Population Starting Statin Therapy or Switching to Higher-Intensity Statin Therapy




Table 3 Baseline Cholesterol-Lowering Medication Utilization

Patients receiving cholesterol-lowering medications		Patients in a commercial plan, N (%) (N = 4,402,866)	Patients in a Medicaid plan, N (%) (N = 2,173,914)	Patients in a Medicare plan, N (%) (N = 7,537,720)	Total population, N (%) (N = 14,114,500)
Statin users, by dosing intensity ^a	Low-intensity statin	54,503 (13.20)	18,684 (21.90)	497,458 (14.60)	570,645 (14.60)
	Moderate-intensity statin	287,968 (69.80)	59,556 (69.70)	2,377,955 (69.70)	2,725,480 (69.70)
	High-intensity statin	70,329 (17.00)	7196 (8.40)	535,758 (15.70)	613,283 (15.70)
	Total	412,800 (9.380)	85,436 (3.93)	3,411,171 (45.25)	3,909,407 (27.70)
Statin and nonstatin cholesterol-lowering medication users ^b	Total	45,327 (1.030)	10,159 (0.47)	364,656 (4.84)	420,142 (2.98)
Nonstatin cholesterol-lowering medication users	Bile acid-binding resins	10,285 (12.39)	1629 (9.06)	92,151 (15.89)	104,065 (15.29)
	Cholesterol absorption inhibitors	13,800 (16.62)	1573 (8.74)	141,624 (24.43)	156,997 (23.06)
	Fibrates	42,835 (51.59)	12,430 (69.09)	279,033 (48.13)	334,298 (49.10)
	Niacin	10,300 (12.41)	2120 (11.78)	64,621 (11.15)	77,041 (11.32)
	Omega-3 fatty acids	15,204 (18.31)	1899 (10.56)	62,893 (10.85)	79,996 (11.75)
	Total	83,024 (1.89)	17,990 (0.83)	579,786 (7.69)	680,800 (4.82)
All cholesterol-lowering medication users ^c	Total	450,497 (10.23)	93,267 (4.29)	3,626,301 (48.11)	4,170,065 (29.54)
Patients aged 40-75 years not receiving cholesterol-lowering medications					
With diabetes		48,796 (3.00)	15,211 (5.10)	213,098 (8.70)	277,105 (6.40)
With hypertension claims but no diabetes		230,743 (14.40)	41,289 (13.90)	761,533 (31.20)	1,033,565 (23.80)
Overall total		1,605,973 (36.48)	297,051 (13.66)	2,442,821 (32.41)	4,345,845 (30.79)

^aSee Table 1 for statin dosing intensity definitions.
^bThese patients are receiving a statin and a nonstatin cholesterol-lowering medication, and these counts are not mutually exclusive of the patients counted under the statin and the nonstatin cholesterol-lowering medication user groups.
^cUnique members who are receiving any cholesterol-lowering medications.

Table 4 Projected Cholesterol-Lowering Medications Utilization

Patients receiving cholesterol-lowering medications		Patients in a commercial plan, N (%) (N = 4,402,866)	Patients in a Medicaid plan, N (%) (N = 2,173,914)	Patients in a Medicare plan, N (%) (N = 7,537,720)	Total population, N (%) (N = 14,114,500)
Statin users, by dosing intensity ^a	Low-intensity statin	27,252 (4.4)	9342 (7.3)	248,729 (6.0)	285,323 (5.8)
	Moderate-intensity statin	392,928 (64.2)	90,642 (70.8)	2,566,826 (61.8)	3,050,396 (62.3)
	High-intensity statin	192,302 (31.4)	28,021 (21.9)	1,336,627 (32.2)	1,556,950 (31.8)
	Total	612,482 (13.91)	128,005 (5.89)	4,152,182 (55.09)	4,892,668 (34.66)
Statin and nonstatin cholesterol-lowering medication users ^b	Total	0 (0)	0 (0)	0 (0)	0 (0)
Nonstatin cholesterol-lowering medication users	Bile acid-binding resins	5667 (22.4)	1000 (19.1)	48,163 (33.4)	54,831 (31.4)
	Cholesterol absorption inhibitors	4801 (19.0)	378 (7.2)	41,549 (28.8)	46,728 (26.8)
	Fibrates	13,270 (52.5)	4204 (80.1)	77,550 (53.8)	95,024 (54.4)
	Niacin	3901 (15.4)	790 (15.1)	21,231 (14.7)	25,922 (14.8)
	Omega-3 fatty acids	7018 (27.8)	535 (10.2)	16,180 (11.2)	23,733 (13.6)
	Total	25,257 (0.57)	5247 (0.24)	144,137 (1.91)	174,641 (1.24)
All cholesterol-lowering medication users ^c	Total	637,739 (14.48)	133,252 (6.13)	4,296,319 (57.00)	5,067,309 (35.90)
Patients aged 40-75 years not receiving cholesterol-lowering medications					
With diabetes claims		0 (0)	0 (0)	0 (0)	0 (0)
With hypertension claims, but no diabetes medication claim		92,297 (6.51)	16,516 (6.42)	304,613 (17.18)	413,426 (11.99)
Overall total		1,418,731 (32.22)	257,067 (11.83)	1,772,803 (23.52)	3,448,601 (24.43)

^aSee Table 1 for statin dosing intensity definitions.
^bThese patients are receiving a statin and a nonstatin cholesterol-lowering medication, and these counts are not mutually exclusive of the patients counted under the statin and the nonstatin cholesterol-lowering medication user groups.
^cUnique members who are receiving any cholesterol-lowering medications.